Sorafenib Combined with Radio-frequency Ablation Compared with Sorafenib Alone in Treatment of Hepatocellular Carcinoma Invading Portal Vein: A Western Randomized Controlled Trial

Autor: Valentina Giorgio, Pietro Gatti, Bruno Santoro, P. Matteucci, Antonio Giorgio, Ferdinando Amendola, Francesca Merola, Carmine Coppola, Maria Gabriella Merola, Antonella Di Sarno, Luca Montesarchio, Andrea Calvanese
Rok vydání: 2016
Předmět:
Male
Niacinamide
Sorafenib
Oncology
Cancer Research
medicine.medical_specialty
Carcinoma
Hepatocellular
Percutaneous
Radiofrequency ablation
medicine.medical_treatment
Antineoplastic Agents
Catheter ablation
urologic and male genital diseases
Gastroenterology
law.invention
03 medical and health sciences
0302 clinical medicine
Randomized controlled trial
law
Internal medicine
medicine
Humans
Combined Modality Therapy
Neoplasm Invasiveness
heterocyclic compounds
neoplasms
Aged
Portal Vein
business.industry
Phenylurea Compounds
Liver Neoplasms
General Medicine
Ablation
medicine.disease
female genital diseases and pregnancy complications
digestive system diseases
030220 oncology & carcinogenesis
Hepatocellular carcinoma
Catheter Ablation
Female
030211 gastroenterology & hepatology
business
medicine.drug
Zdroj: Anticancer Research. 36:6179-6184
ISSN: 1791-7530
0250-7005
DOI: 10.21873/anticanres.11211
Popis: Aim To compare in a randomized controlled trial (RCT) 3-year survival of cirrhotic patients with hepatocellular carcinoma (HCC) accompanied by portal vein tumor thrombus (PVTT) treated with sorafenib plus percutaneous radiofrequency ablation (RFA) of both intraparenchymal HCC and PVTT (combination Group) or sorafenib alone (sorafenib-alone Group). Patients and methods Ninety-nine consecutive Child A cirrhotics were randomized to receive RFA of both HCC and main portal vein tumor thrombus (MPVTT) plus sorafenib (n=49) or sorafenib alone (n=50). Results One-, 2- and 3-year survival rates were 60%, 35% and 26%, respectively, in the combination group and 37% and 0 % at 1- and 2-year, respectively, in the sorafenib alone group. At multivariate analysis, the combination of RFA of both HCC and MPVTT was the only factor predicting survival. Conclusion Use of RFA of both HCC and MPVTT plus sorafenib significantly increases 3-year survival compared to sorafenib alone.
Databáze: OpenAIRE
Externí odkaz: